Literature DB >> 14623077

Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1-4) expression in vivo.

Oleksandr Minchenko1, Iryna Opentanova, Jaime Caro.   

Abstract

When oxygen becomes limiting, cells shift primarily to a glycolytic mode for generation of energy. A key regulator of glycolytic flux is fructose-2,6-bisphosphate (F-2,6-BP), a potent allosteric regulator of 6-phosphofructo-1-kinase (PFK-1). The levels of F-2,6-BP are maintained by a family of bifunctional enzymes, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB or PFK-2), which have both kinase and phosphatase activities. Each member of the enzyme family is characterized by their phosphatase:kinase activity ratio (K:B) and their tissue-specific expression. Previous work demonstrated that one of the PFK-2 isozyme genes, PFKFB-3, was induced by hypoxia through the hypoxia-inducible factor-1 (HIF-1) pathway. In this study we examined the basal and hypoxic expression of three members of this family in different organs of mice. Our findings indicate that all four isozymes (PFKFB-1-4) are responsive to hypoxia in vivo. However, their basal level of expression and hypoxia responsiveness varies in the different organs studied. Particularly, PFKFB-1 is highly expressed in liver, heart and skeletal muscle, with the highest response to hypoxia found in the testis. PFKFB-2 is mainly expressed in the lungs, brain and heart. However, the highest hypoxia responses are found only in liver and testis. PFKFB-3 has a variable low basal level of expression in all organs, except skeletal muscle, where it is highly expressed. Most importantly, its hypoxia responsiveness is the most ample of all three genes, being strongly induced in the lungs, liver, kidney, brain, heart and testis. Further studies showed that PFKFB-1 and PFKFB-2 were highly responsive to hypoxia mimics such as transition metals, iron chelators and inhibitors of HIF hydroxylases, suggesting that the hypoxia responsiveness of these genes is also regulated by HIF proteins. In summary, our data demonstrate that PFK-2 genes are responsive to hypoxia in vivo, indicating a physiological role in the adaptation of the organism to environmental or localized hypoxia/ischemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14623077     DOI: 10.1016/s0014-5793(03)01179-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  66 in total

Review 1.  Targeting lactate metabolism for cancer therapeutics.

Authors:  Joanne R Doherty; John L Cleveland
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

2.  Molecular basis of the fructose-2,6-bisphosphatase reaction of PFKFB3: transition state and the C-terminal function.

Authors:  Michael C Cavalier; Song-Gun Kim; David Neau; Yong-Hwan Lee
Journal:  Proteins       Date:  2012-01-31

3.  Regulation of glycolysis in head and neck squamous cell carcinoma.

Authors:  Dhruv Kumar
Journal:  Postdoc J       Date:  2017-01

Review 4.  Sirtuin 3, Endothelial Metabolic Reprogramming, and Heart Failure With Preserved Ejection Fraction.

Authors:  Heng Zeng; Jian-Xiong Chen
Journal:  J Cardiovasc Pharmacol       Date:  2019-10       Impact factor: 3.105

5.  Analysis and interpretation of transcriptomic data obtained from extended Warburg effect genes in patients with clear cell renal cell carcinoma.

Authors:  Edward Sanders; Svenja Diehl
Journal:  Oncoscience       Date:  2015-02-17

Review 6.  Hypoxia-induced alternative splicing in human diseases: the pledge, the turn, and the prestige.

Authors:  Subhashis Natua; Cheemala Ashok; Sanjeev Shukla
Journal:  Cell Mol Life Sci       Date:  2021-01-02       Impact factor: 9.261

Review 7.  Heterogeneity of glycolysis in cancers and therapeutic opportunities.

Authors:  Marc O Warmoes; Jason W Locasale
Journal:  Biochem Pharmacol       Date:  2014-08-02       Impact factor: 5.858

8.  HIF-1: an age-dependent regulator of lens cell proliferation.

Authors:  Ying-Bo Shui; Jeffrey M Arbeit; Randall S Johnson; David C Beebe
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-06-27       Impact factor: 4.799

9.  Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.

Authors:  Brian F Clem; Julie O'Neal; Gilles Tapolsky; Amy L Clem; Yoannis Imbert-Fernandez; Daniel A Kerr; Alden C Klarer; Rebecca Redman; Donald M Miller; John O Trent; Sucheta Telang; Jason Chesney
Journal:  Mol Cancer Ther       Date:  2013-05-14       Impact factor: 6.261

10.  Ablation of SIRT3 causes coronary microvascular dysfunction and impairs cardiac recovery post myocardial ischemia.

Authors:  Xiaochen He; Heng Zeng; Jian-Xiong Chen
Journal:  Int J Cardiol       Date:  2016-04-16       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.